Drugs / Synthetic long peptide personalized cancer vaccine
Synthetic long peptide personalized cancer vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06529822 | Mar 2025 → Jan 2030 expected | gastroesophageal adenocarcinoma, infiltrating bladder urothelial carcinoma, melanoma, non-small cell lung carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synthetic long peptide personalized cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06529822 ↗ |
| Modality | Vaccine | “personalized cancer vaccine strategy” NCT06529822 ↗ |
| Route | Intramuscular | “All study injections will be given intramuscularly” NCT06529822 ↗ |